Adicet Bio, Inc.
- ACET
- NASDAQ
- Biotechnology
- Allogeneic Cell Therapy
- Gamma Delta T Cells
- Cancer Immunotherapy
$4.57
Today −11.09%Quote Oct 16, 2026, 08:00 PM UTC
−49.28%over the last month
Max drawdown −50.2%From 1-month high −50.2%3 months −42.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$42.8M
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$27.00
+490.8% from here
Floor
$4.07
10.9% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ACETPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q4 2018 revenue $163.6M
- Human Health$85.0M51.9%
- Pharmaceutical Ingredients$42.0M25.7%
- Performance Chemicals$36.6M22.4%
Industry
Biotechnology
Employees
102